Fineotex Chemical Limited has announced a comprehensive plant visit for investors and analysts at its manufacturing facility in Ambernath, Maharashtra, scheduled for March 24, 2026. The company has formally notified both the Bombay Stock Exchange and National Stock Exchange of India about this engagement under SEBI Regulation 30 compliance requirements.

Scheduled Plant Visit Details

The plant visit is organized as an in-person event at the company's Ambernath facility, located at Anand Nagar, Additional M.I.D.C., Ambernath, Maharashtra – 421506. The comprehensive facility tour is scheduled from 08:00 AM to 05:00 PM IST on Tuesday, March 24, 2026.

Participating Investment Firms

The company will host a diverse group of 12 investment firms and analysts during the facility visit:

Regulatory Compliance and Information Disclosure

Fineotex Chemical has emphasized its commitment to regulatory compliance by formally notifying stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has specifically stated that no price-sensitive information will be discussed or disclosed during the plant visit, ensuring adherence to fair disclosure practices.

Visit Logistics and Flexibility

The company has indicated that the schedule for the plant visit is subject to change due to potential exigencies on the part of analysts or institutional investors. This flexibility demonstrates the company's commitment to accommodating the schedules of participating investment professionals while maintaining operational efficiency.

The notification was signed by Sunny Parmar, Company Secretary & Compliance Officer, and formally communicated to both major Indian stock exchanges where the company is listed with codes 533333 (BSE) and FCL (NSE).

Fineotex Chemical Limited has submitted its quarterly monitoring agency report for Q3FY26 to the Bombay Stock Exchange and National Stock Exchange, providing updated details on the utilization of proceeds raised through its preferential issue completed in May 2024.

Issue Details and Revised Proceeds Status

The specialty chemicals company originally planned to raise INR 280.350 crores through a preferential issue of equity shares and convertible warrants during May 13-22, 2024. However, due to undersubscription, the actual net proceeds were revised downwards to INR 91.963 crores.

Monitoring Agency Assessment

ICRA Limited, appointed as the monitoring agency, confirmed that the utilization of issue proceeds remains in line with the stated objects of the issue. The report indicates no material deviations from the original plan disclosed in the offer document.

Revised Proceeds Utilization Breakdown

The company has allocated the available proceeds across three primary objectives with costs revised proportionally due to undersubscription:

General Corporate Purpose Utilization

The report provides specific details on how general corporate purpose funds totaling INR 9.785 crores have been utilized across different quarters:

Investment of Unutilized Proceeds

The company has deployed INR 35.682 crores of unutilized proceeds in mutual fund investments, generating returns of INR 0.186 crores with a market value of INR 35.867 crores as of quarter-end.

Implementation Timeline

All objects remain on schedule with completion targeted by September 30, 2030. The monitoring agency found no delays in implementation across any of the stated objectives despite the significant reduction in proceeds due to undersubscription.

The monitoring agency report emphasizes that it does not constitute commentary on the quality of issue objects or assurance on spending outcomes, but provides an objective view of proceeds utilization based on information provided by the issuer.